Middle East Journal of Rehabilitation and Health Studies

Published by: Kowsar
Crossmark

Effect of Botulinum Toxin A (BTX-A) Injection into Denervated Muscles on Synkinesis and Symmetry in Patients with Facial Nerve Paralysis

Abbas Ali Pourmomeny 1 , * and Elham Pourali 1
Authors Information
1 Department of Physical Therapy, School of Rehabilitation Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
Article information
  • Middle East Journal of Rehabilitation and Health: April 30, 2019, 6 (2); e81931
  • Published Online: February 18, 2019
  • Article Type: Review Article
  • Received: July 10, 2018
  • Revised: October 13, 2018
  • Accepted: December 26, 2018
  • DOI: 10.5812/mejrh.81931

To Cite: Pourmomeny A A, Pourali E. Effect of Botulinum Toxin A (BTX-A) Injection into Denervated Muscles on Synkinesis and Symmetry in Patients with Facial Nerve Paralysis, Middle East J Rehabil Health Stud. 2019 ; 6(2):e81931. doi: 10.5812/mejrh.81931.

Abstract
Copyright © 2019, Middle East Journal of Rehabilitation and Health Studies. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Discussion
5. Conclusions
Acknowledgements
Footnotes
References
  • 1. Peitersen E. Bell's palsy: The spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl. 2002;(549):4-30. [PubMed: 12482166].
  • 2. Roob G, Fazekas F, Hartung HP. Peripheral facial palsy: Etiology, diagnosis and treatment. Eur Neurol. 1999;41(1):3-9. doi: 10.1159/000007990. [PubMed: 9885321].
  • 3. Cronin GW, Steenerson RL. The effectiveness of neuromuscular facial retraining combined with electromyography in facial paralysis rehabilitation. Otolaryngol Head Neck Surg. 2003;128(4):534-8. doi: 10.1016/S0194-59980300005-6. [PubMed: 12707657].
  • 4. de Maio M, Bento RF. Botulinum toxin in facial palsy: An effective treatment for contralateral hyperkinesis. Plast Reconstr Surg. 2007;120(4):917-27. discussion 928. doi: 10.1097/01.prs.0000244311.72941.9a. [PubMed: 17805119].
  • 5. Pepper JP, Kim JC. Selective chemodenervation with botulinum toxin in facial nerve disorders. Oper Tech Otolaryngol Head Neck Surg. 2012;23(4):297-305. doi: 10.1016/j.otot.2012.10.001.
  • 6. Crumley RL. Mechanisms of synkinesis. Laryngoscope. 1979;89(11):1847-54. doi: 10.1288/00005537-197911000-00020. [PubMed: 502707].
  • 7. Chuang DC, Chang TN, Lu JC. Postparalysis facial synkinesis: Clinical classification and surgical strategies. Plast Reconstr Surg Glob Open. 2015;3(3). e320. doi: 10.1097/GOX.0000000000000283. [PubMed: 25878931]. [PubMed Central: PMC4387142].
  • 8. Mehta RP, Hadlock TA. Botulinum toxin and quality of life in patients with facial paralysis. Arch Facial Plast Surg. 2008;10(2):84-7. doi: 10.1001/archfaci.10.2.84. [PubMed: 18347234].
  • 9. Grundt B. Surgical treatment of seventh nerve paralysis. Br J Plast Surg. 1950;3(1):50-5. doi: 10.1016/S0007-1226(50)80009-7. [PubMed: 15411506].
  • 10. Pourmomeny AA, Zadmehre H, Mirshamsi M, Mahmodi Z. Prevention of synkinesis by biofeedback therapy: A randomized clinical trial. Otol Neurotol. 2014;35(4):739-42. doi: 10.1097/MAO.0000000000000217. [PubMed: 24317208].
  • 11. Pourmomeny AA, Asadi S. Management of synkinesis and asymmetry in facial nerve palsy: A review article. Iran J Otorhinolaryngol. 2014;26(77):251-6. [PubMed: 25320703]. [PubMed Central: PMC4196449].
  • 12. May M. Management of facial hyperkinesis. Overview of hyperkinesis. In: May M, Schaitkin BM, editors. The facial nerve. 2nd ed. New York: Thieme; 2000.
  • 13. Scott AB. Development of botulinum toxin therapy. Dermatol Clin. 2004;22(2):131-3. v. doi: 10.1016/S0733-8635(03)00019-6. [PubMed: 15222571].
  • 14. Kostrzewa RM, Segura-Aguilar J. Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea. Neurotox Res. 2007;12(4):275-90. doi: 10.1007/BF03033911. [PubMed: 18201955].
  • 15. Chen S. Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments. Toxins (Basel). 2012;4(10):913-39. doi: 10.3390/toxins4100913. [PubMed: 23162705]. [PubMed Central: PMC3496996].
  • 16. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324(17):1186-94. doi: 10.1056/NEJM199104253241707. [PubMed: 2011163].
  • 17. Ward AB, Molenaers G, Colosimo C, Berardelli A. Clinical value of botulinum toxin in neurological indications. Eur J Neurol. 2006;13 Suppl 4:20-6. doi: 10.1111/j.1468-1331.2006.01650.x. [PubMed: 17112346].
  • 18. Boroojerdi B, Ferbert A, Schwarz M, Herath H, Noth J. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry. 1998;65(1):111-4. doi: 10.1136/jnnp.65.1.111. [PubMed: 9667571]. [PubMed Central: PMC2170154].
  • 19. Ito H, Ito H, Nakano S, Kusaka H. Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation. Acta Neurol Scand. 2007;115(4):271-4. doi: 10.1111/j.1600-0404.2006.00746.x. [PubMed: 17376126].
  • 20. Borodic G, Bartley M, Slattery W, Glasscock M, Johnson E, Malazio C, et al. Botulinum toxin for aberrant facial nerve regeneration: double-blind, placebo-controlled trial using subjective endpoints. Plast Reconstr Surg. 2005;116(1):36-43. doi: 10.1097/01.PRS.0000169689.27829.C4. [PubMed: 15988245].
  • 21. Lee JM, Choi KH, Lim BW, Kim MW, Kim J. Half-mirror biofeedback exercise in combination with three botulinum toxin A injections for long-lasting treatment of facial sequelae after facial paralysis. J Plast Reconstr Aesthet Surg. 2015;68(1):71-8. doi: 10.1016/j.bjps.2014.08.067. [PubMed: 25444667].
  • 22. Fortuna R, Vaz MA, Youssef AR, Longino D, Herzog W. Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox). J Biomech. 2011;44(1):39-44. doi: 10.1016/j.jbiomech.2010.08.020. [PubMed: 20828699].
  • 23. Fortuna R, Vaz MA, Sawatsky A, Hart DA, Herzog W. A clinically relevant BTX-A injection protocol leads to persistent weakness, contractile material loss, and an altered mRNA expression phenotype in rabbit quadriceps muscles. J Biomech. 2015;48(10):1700-6. doi: 10.1016/j.jbiomech.2015.05.018.
  • 24. von Lindern JJ, Niederhagen B, Appel T, Berge S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: An alternative treatment. Plast Reconstr Surg. 2001;107(2):327-32. doi: 10.1097/00006534-200102000-00004. [PubMed: 11214045].
  • 25. Lee CJ, Kim SG, Kim YJ, Han JY, Choi SH, Lee SI. Electrophysiologic change and facial contour following botulinum toxin A injection in square faces. Plast Reconstr Surg. 2007;120(3):769-78. doi: 10.1097/01.prs.0000271068.71399.ae. [PubMed: 17700130].
  • 26. Choi KH, Rho SH, Lee JM, Jeon JH, Park SY, Kim J. Botulinum toxin injection of both sides of the face to treat post-paralytic facial synkinesis. J Plast Reconstr Aesthet Surg. 2013;66(8):1058-63. doi: 10.1016/j.bjps.2013.04.012. [PubMed: 23683725].
  • 27. Yaraskavitch M, Leonard T, Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech. 2008;41(4):897-902. doi: 10.1016/j.jbiomech.2007.11.016. [PubMed: 18184613].
  • 28. Toffola ED, Furini F, Redaelli C, Prestifilippo E, Bejor M. Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy. Disabil Rehabil. 2010;32(17):1414-8. doi: 10.3109/09638280903514697. [PubMed: 20156046].
  • 29. Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans. Mov Disord. 1997;12(1):89-94. doi: 10.1002/mds.870120115. [PubMed: 8990059].
  • 30. Dall'Angelo A, Mandrini S, Sala V, Pavese C, Carlisi E, Comelli M, et al. Platysma synkinesis in facial palsy and botulinum toxin type A. Laryngoscope. 2014;124(11):2513-7. doi: 10.1002/lary.24732. [PubMed: 24764160].
  • 31. Wei LA, Diels J, Lucarelli MJ. Treating buccinator with botulinum toxin in patients with facial synkinesis: A previously overlooked target. Ophthalmic Plast Reconstr Surg. 2016;32(2):138-41. doi: 10.1097/IOP.0000000000000449. [PubMed: 26325382].
  • 32. Mountain RE, Murray JAM, Quaba A. Management of facial synkinesis with Clostridium botulinum toxin injection. Clin Otolaryngol. 1992;17(3):223-4. doi: 10.1111/j.1365-2273.1992.tb01831.x.
  • 33. Roggenkamper P, Laskawi R, Damenz W, Schroder M, Nussgens Z. Orbicular synkinesis after facial paralysis: Treatment with botulinum toxin. Doc Ophthalmol. 1994;86(4):395-402. doi: 10.1007/BF01204598. [PubMed: 7835177].
  • 34. Chua CN, Quhill F, Jones E, Voon LW, Ahad M, Rowson N. Treatment of aberrant facial nerve regeneration with botulinum toxin A. Orbit. 2004;23(4):213-8. doi: 10.1080/01676830490512233. [PubMed: 15590522].
  • 35. Filipo R, Spahiu I, Covelli E, Nicastri M, Bertoli GA. Botulinum toxin in the treatment of facial synkinesis and hyperkinesis. Laryngoscope. 2012;122(2):266-70. doi: 10.1002/lary.22404. [PubMed: 22252570].
  • 36. Navarrete Alvaro ML, Junyent J, Torrent L. [Botulinum toxin and facial palsy. Our experience]. Acta Otorrinolaringol Esp. 2010;61(4):277-81. Spanish. doi: 10.1016/j.otorri.2010.02.009. [PubMed: 20400055].
  • 37. Azuma T, Nakamura K, Takahashi M, Ohyama S, Toda N, Iwasaki H, et al. Mirror biofeedback rehabilitation after administration of single-dose botulinum toxin for treatment of facial synkinesis. Otolaryngol Head Neck Surg. 2012;146(1):40-5. doi: 10.1177/0194599811424125. [PubMed: 21965443].
  • 38. Monini S, De Carlo A, Biagini M, Buffoni A, Volpini L, Lazzarino AI, et al. Combined protocol for treatment of secondary effects from facial nerve palsy. Acta Otolaryngol. 2011;131(8):882-6. doi: 10.3109/00016489.2011.577447. [PubMed: 21534714].
  • 39. Pourmomeny AA, Asadi S, Cheatsaz A. Management of facial synkinesis with a combination of BTX-A and biofeedback: A randomized trial. Iran J Otorhinolaryngol. 2015;27(83):409-15. [PubMed: 26788484]. [PubMed Central: PMC4709755].
  • 40. Roggenkamper P, Laskawi R, Damenz W, Schroder M, Nussgens Z. [Involuntary lid closure caused by defective healing of facial paralysis and its treatment with botulinum toxin]. Klin Monbl Augenheilkd. 1991;198(4):268-70. German. doi: 10.1055/s-2008-1045963. [PubMed: 1861404].
  • 41. do Nascimento Remigio AF, Salles AG, de Faria JCM, Ferreira MC. Comparison of the efficacy of Onabotulinum toxin A and Abobotulinum toxin A at the 1: 3 conversion ratio for the treatment of asymmetry after long-term facial paralysis. Plast Reconstr Surg. 2015;135(1):239-49. doi: 10.1097/prs.0000000000000800.
  • 42. Kim J. Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otol Neurotol. 2013;34(2):319-24. doi: 10.1097/MAO.0b013e31827c9f58. [PubMed: 23444480].
  • 43. Gooriah R, Ahmed F. Therapeutic uses of botulinum toxin. J Clin Toxicol. 2014;5(1). doi: 10.4172/2161-0495.1000225.
  • 44. May M, Croxson GR, Klein SR. Bell's palsy: Management of sequelae using EMG rehabilitation, botulinum toxin, and surgery. Am J Otol. 1989;10(3):220-9. [PubMed: 2750869].
  • 45. Beller M, Middaugh JP. Repeated type E botulism in an Alaskan Eskimo. N Engl J Med. 1990;322(12):855. doi: 10.1056/NEJM199003223221220. [PubMed: 2308624].
  • 46. Dressler D, Adib Saberi F. Botulinum toxin: Mechanisms of action. Eur Neurol. 2005;53(1):3-9. doi: 10.1159/000083259. [PubMed: 15650306].
  • 47. Ansved T, Odergren T, Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology. 1997;48(5):1440-2. doi: 10.1212/WNL.48.5.1440. [PubMed: 9153487].
  • 48. Girlanda P, Vita G, Nicolosi C, Milone S, Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry. 1992;55(9):844-5. doi: 10.1136/jnnp.55.9.844. [PubMed: 1328540]. [PubMed Central: PMC1015114].
  • 49. Couch SM, Chundury RV, Holds JB. Subjective and objective outcome measures in the treatment of facial nerve synkinesis with onabotulinumtoxinA (Botox). Ophthalmic Plast Reconstr Surg. 2014;30(3):246-50. doi: 10.1097/IOP.0000000000000086. [PubMed: 24807539].
  • 50. Laskawi R, Damenz W, Roggenkamper P, Baetz A. Botulinum toxin treatment in patients with facial synkinesis. Eur Arch Otorhinolaryngol. 1994:S195-9. [PubMed: 10774349].
  • 51. Martinkaityte P, Griškevičiūtė R, Vieversyte M, Varžaitytė L, Savickas R. Rehabilitation strategies for facial nerve neuropathy. Health Sci. 2015;25(6):105-10.
  • 52. Sadiq SA, Khwaja S, Saeed SR. Botulinum toxin to improve lower facial symmetry in facial nerve palsy. Eye (Lond). 2012;26(11):1431-6. doi: 10.1038/eye.2012.189. [PubMed: 22975654]. [PubMed Central: PMC3496102].
  • 53. Cakmak MA, Sahin S, Cinar N, Karsidag S. Complications of botulinum toxin application: differences between hemifacial spasm and post-facial palsy synkinesis. Acta Neurol Belg. 2014;114(4):331. doi: 10.1007/s13760-014-0287-x. [PubMed: 24647748].
  • 54. Kim J, Lee HR, Jeong JH, Lee WS. Features of facial asymmetry following incomplete recovery from facial paralysis. Yonsei Med J. 2010;51(6):943-8. doi: 10.3349/ymj.2010.51.6.943. [PubMed: 20879064]. [PubMed Central: PMC2995977].
  • 55. Beurskens CH, Oosterhof J, Nijhuis-van der Sanden MW. Frequency and location of synkineses in patients with peripheral facial nerve paresis. Otol Neurotol. 2010;31(4):671-5. doi: 10.1097/MAO.0b013e3181d8d84d. [PubMed: 20351606].
  • 56. Kayhan FT, Zurakowski D, Rauch SD. Toronto facial grading system: Interobserver reliability. Otolaryngol Head Neck Surg. 2000;122(2):212-5. doi: 10.1016/S0194-5998(00)70241-5. [PubMed: 10652392].
  • 57. Mehdizadeh OB, Diels J, White WM. Botulinum toxin in the treatment of facial paralysis. Facial Plast Surg Clin North Am. 2016;24(1):11-20. doi: 10.1016/j.fsc.2015.09.008. [PubMed: 26611697].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments